['psoriatic arthritis']
['etanercept', 'methotrexate', 'placebo to etanercept', 'placebo to methotrexate']

        Key Inclusion Criteria:

          -  Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification
             Criteria for Psoriatic Arthritis (CASPAR) criteria.

          -  Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.

          -  Subject has an active psoriatic skin lesion

          -  Subject is naïve to etanercept and any other biologic for the treatment for PsA or
             psoriasis.

          -  Subject has no prior use of methotrexate for PsA.

          -  Subject has no history of tuberculosis

          -  Subject has a negative test for tuberculosis, hepatitis B and C.

        Exclusion Criteria:

          -  Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or
             immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.

          -  Subject has any active infection (including chronic or localized infections) for which
             anti-infectives were indicated within 4 weeks prior to the first dose of
             investigational product.

          -  Subject has a serious infection, defined as requiring hospitalization or intravenous
             anti-infectives within 8 weeks prior to the first dose of investigational product.
      